세계의 말초동맥질환 시장 : 제품 유형별, 최종사용자별 - 기회 분석 및 산업 예측(2024-2035년)

Peripheral Artery Disease Market By Product Type (Devices, Drugs), By End User (Hospitals, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035

US $ 5,730 ￦ 7,966,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,346,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 말초동맥질환 시장은 2023년 45억 달러로 평가되며 2024년부터 2035년까지 연평균 7.7% 성장하여 2035년에는 108억 달러에 달할 것으로 추정됩니다. 말초동맥질환은 사지(보통 다리)에 혈액을 공급하는 동맥이 좁아지거나 막히는 것을 특징으로 하는 질환입니다. 이는 동맥에 지방 침착물(플라크)이 쌓여 동맥경화증으로 알려진 동맥경화증으로 인해 발생합니다. 그 결과 다리로 가는 혈류가 제한되어 다리 통증, 경련, 무감각, 무력감, 특히 운동 시 다리 통증과 같은 증상이 나타납니다. 말초동맥질환의 치료는 증상을 관리하고 합병증을 예방하며 혈류를 개선하는 것을 목표로 합니다. 막힌 동맥을 열어 혈류를 회복시키기 위해 시술이나 수술이 필요할 수 있습니다. 여기에는 혈관 성형술(풍선으로 동맥을 넓혀주는 시술)과 스텐트 삽입술(동맥을 열어주는 시술)이 포함됩니다.

말초동맥질환 시장의 성장세는 노인 인구의 증가와 최소침습 수술 기술의 발전에 기인합니다. 세계보건기구(WHO)의 2022년 보고서에 따르면, 노인 인구(60세 이상)는 전 세계 인구의 약 22%를 차지할 것으로 추정됩니다. 나이가 들어감에 따라, 특히 당뇨병, 고혈압, 흡연력 등 다른 심혈관 위험 요인을 가진 사람들 사이에서 말초 동맥 질환이 발생할 위험이 증가합니다. 많은 국가에서 인구 통계가 고령층으로 이동함에 따라 말초 동맥 질환의 발생률과 유병률이 증가할 것으로 예상되며, National Library of Medicine의 2023년 보고서에 따르면 70세 이상에서 말초 동맥 질환의 발생률이 20%까지 증가할 것으로 예상됩니다. 보고되고 있습니다. 이처럼 노인 인구는 말초동맥질환 발병률이 높기 때문에 노인 인구의 증가는 말초동맥질환 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. 또한, 최소침습적 시술의 기술 발전은 말초동맥질환 시장의 주요 촉진요인으로 부상하고 있으며, 진단 및 치료의 상황을 변화시키고 있습니다. 혈관성형술, 스텐트삽입술, 죽상동맥절제술과 같은 최소침습적 기술은 기존의 개복수술에 대한 보다 안전하고 효과적인 대안을 제공함으로써 말초동맥질환의 관리에 혁명을 일으켰습니다. 이러한 시술은 기존 수술적 접근 방식에 비해 절개창이 작고, 주변 조직에 대한 외상이 적으며, 회복 시간이 짧고, 합병증 위험이 낮습니다. 예를 들어, 선도적 인 의료기기 제조업체 인 Medtronic Plc는 완전한 SE 혈관 스텐트 시스템을 제공합니다. 완전한 SE 혈관 스텐트 시스템은 표재성 대퇴 동맥과 근위 슬와 동맥의 말초 동맥 질환을 치료하도록 설계되었습니다. 이 스텐트는 막힌 동맥을 열고 혈관 성형술 후 동맥을 지지하여 혈류를 회복하도록 설계되었습니다. 말초동맥질환 시장은 제품 유형, 최종사용자, 지역별로 세분화됩니다. 제품 유형별로 시장은 약물과 장치로 구분됩니다. 최종사용자별로 시장은 병원, 전문 클리닉, 외래 수술 센터로 나뉩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아태평양), 남미(브라질, 사우디아라비아, 아프리카, 기타 남미 지역)로 분석됩니다. 말초동맥질환 시장에서 활동하는 주요 기업으로는 Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott 등이 있습니다. 주요 기업들은 말초동맥질환 시장의 제품 포트폴리오를 개선하기 위한 주요 개발 전략으로 제품 승인을 채택하고 있으며, 이해관계자를 위한 주요 이점은 다음과 같습니다.

• 이 보고서는 2023년부터 2035년까지 말초동맥질환 시장 분석의 시장 부문, 현재 동향, 추정 및 추세, 역학에 대한 정량적 분석을 제공하여 일반적인 말초동맥질환 시장 기회를 식별합니다.
• 시장 촉진요인, 시장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 공급업체의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 말초 동맥 질환 시장 세분화에 대한 심층 분석은 시장 기회를 결정하는 데 도움이됩니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서는 지역 및 세계 말초동맥질환 시장 동향, 주요 기업, 시장 부문, 응용 분야, 시장 성장 전략에 대한 분석을 담고 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 말초동맥질환 시장 : 제품 유형별

• 개요
• 디바이스
  • 디바이스 말초동맥질환 시장 : 디바이스 유형별
• 의약품
  • 약물 유형별 말초동맥질환 시장

제5장 말초동맥질환 시장 : 최종사용자별

• 개요
• 병원
• 전문 클리닉

제6장 말초동맥질환 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 호주
  • 인도
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제7장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2023년

제8장 기업 개요

• Koninklijke Philips N.V.
• B. Braun Melsungen AG
• Medtronic
• Bayer AG
• Boston Scientific Corporation
• Becton Dickinson and Company
• Terumo Medical Corporation
• Biotronik SE & Co. KG
• Cardinal Health
• Abbott Laboratories

ksm

영문 목차

영문목차

The global peripheral artery disease market was valued at $4.5 billion in 2023, and is estimated to reach $10.8 billion by 2035, growing at a CAGR of 7.7% from 2024 to 2035. Peripheral artery disease is a condition characterized by the narrowing or blockage of arteries that supply blood to the limbs, typically the legs. This occurs due to the buildup of fatty deposits (plaques) in the arteries, a process known as atherosclerosis. As a result, blood flow to the legs is restricted, leading to symptoms such as leg pain, cramping, numbness, and weakness, particularly during physical activity. Treatment for peripheral artery disease aims to manage symptoms, prevent complications, and improve blood flow. Procedures or surgeries may be required to open blocked arteries and restore blood flow. These can include angioplasty (where a balloon is used to widen the artery) or stent placement (to keep the artery open).The peripheral artery disease market growth is attributed to rise in geriatric population, and technological advancements in minimally invasive surgical technology. According to 2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected to contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected to escalate. According to the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases to as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected to positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives to traditional open surgeries. These procedures involve smaller incisions, reduced trauma to surrounding tissues, shorter recovery times, and lower risk of complications compared to conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed to treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed to open clogged arteries and restore blood flow by providing support to the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected to drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated into drugs and devices. By end user, the market is divided into hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy to improve the product portfolio of the peripheral artery disease marketKey Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peripheral artery disease market analysis from 2023 to 2035 to identify the prevailing peripheral artery disease market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the peripheral artery disease market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global peripheral artery disease market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

• Devices
  • Devices type
  • Peripheral Angioplasty Balloons
  • Peripheral Stents
  • Peripheral Catheters
  • Inferior Vena Cava Filters
  • Plaque Modification Devices
  • Hemodynamic Flow Alteration Devices
  • Peripheral Accessories
• Drugs
  • Drug Type
  • Antiplatelet medicines
  • Statins
  • Anti Hypertensive Medication
  • Others

By End User

• Specialty Clinics
• Hospitals

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Koninklijke Philips N.V.
• B. Braun Melsungen AG
• Medtronic
• Bayer AG
• Boston Scientific Corporation
• Becton Dickinson and Company
• Terum

Medical Corporation

• Biotronik SE & Co. KG
• Cardinal Health
• Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Devices
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Devices Peripheral Artery Disease Market by Devices type
• 4.3. Drugs
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Drugs Peripheral Artery Disease Market by Drug Type

CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Hospitals
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Specialty Clinics
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by Product Type
  • 6.2.3. Market size and forecast, by End User
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Market size and forecast, by Product Type
    • 6.2.4.1.2. Market size and forecast, by End User
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Market size and forecast, by Product Type
    • 6.2.4.2.2. Market size and forecast, by End User
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Market size and forecast, by Product Type
    • 6.2.4.3.2. Market size and forecast, by End User
• 6.3. Europe
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by Product Type
  • 6.3.3. Market size and forecast, by End User
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Market size and forecast, by Product Type
    • 6.3.4.1.2. Market size and forecast, by End User
    • 6.3.4.2. France
    • 6.3.4.2.1. Market size and forecast, by Product Type
    • 6.3.4.2.2. Market size and forecast, by End User
    • 6.3.4.3. UK
    • 6.3.4.3.1. Market size and forecast, by Product Type
    • 6.3.4.3.2. Market size and forecast, by End User
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Market size and forecast, by Product Type
    • 6.3.4.4.2. Market size and forecast, by End User
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Market size and forecast, by Product Type
    • 6.3.4.5.2. Market size and forecast, by End User
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Market size and forecast, by Product Type
    • 6.3.4.6.2. Market size and forecast, by End User
• 6.4. Asia-Pacific
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by Product Type
  • 6.4.3. Market size and forecast, by End User
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Market size and forecast, by Product Type
    • 6.4.4.1.2. Market size and forecast, by End User
    • 6.4.4.2. China
    • 6.4.4.2.1. Market size and forecast, by Product Type
    • 6.4.4.2.2. Market size and forecast, by End User
    • 6.4.4.3. Australia
    • 6.4.4.3.1. Market size and forecast, by Product Type
    • 6.4.4.3.2. Market size and forecast, by End User
    • 6.4.4.4. India
    • 6.4.4.4.1. Market size and forecast, by Product Type
    • 6.4.4.4.2. Market size and forecast, by End User
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Market size and forecast, by Product Type
    • 6.4.4.5.2. Market size and forecast, by End User
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Market size and forecast, by Product Type
    • 6.4.4.6.2. Market size and forecast, by End User
• 6.5. LAMEA
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by Product Type
  • 6.5.3. Market size and forecast, by End User
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Market size and forecast, by Product Type
    • 6.5.4.1.2. Market size and forecast, by End User
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Market size and forecast, by Product Type
    • 6.5.4.2.2. Market size and forecast, by End User
    • 6.5.4.3. South Africa
    • 6.5.4.3.1. Market size and forecast, by Product Type
    • 6.5.4.3.2. Market size and forecast, by End User
    • 6.5.4.4. Rest of LAMEA
    • 6.5.4.4.1. Market size and forecast, by Product Type
    • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product mapping of top 10 player
• 7.4. Competitive dashboard
• 7.5. Competitive heatmap
• 7.6. Top player positioning, 2023

CHAPTER 8: COMPANY PROFILES

• 8.1. Koninklijke Philips N.V.
  • 8.1.1. Company overview
  • 8.1.2. Key executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. B. Braun Melsungen AG
  • 8.2.1. Company overview
  • 8.2.2. Key executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
  • 8.2.7. Key strategic moves and developments
• 8.3. Medtronic
  • 8.3.1. Company overview
  • 8.3.2. Key executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
  • 8.3.7. Key strategic moves and developments
• 8.4. Bayer AG
  • 8.4.1. Company overview
  • 8.4.2. Key executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
  • 8.4.7. Key strategic moves and developments
• 8.5. Boston Scientific Corporation
  • 8.5.1. Company overview
  • 8.5.2. Key executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. Becton Dickinson and Company
  • 8.6.1. Company overview
  • 8.6.2. Key executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
  • 8.6.7. Key strategic moves and developments
• 8.7. Terumo Medical Corporation
  • 8.7.1. Company overview
  • 8.7.2. Key executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. Biotronik SE & Co. KG
  • 8.8.1. Company overview
  • 8.8.2. Key executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
  • 8.8.7. Key strategic moves and developments
• 8.9. Cardinal Health
  • 8.9.1. Company overview
  • 8.9.2. Key executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
  • 8.9.7. Key strategic moves and developments
• 8.10. Abbott Laboratories
  • 8.10.1. Company overview
  • 8.10.2. Key executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance
  • 8.10.7. Key strategic moves and developments

관련자료